Pulse Biosciences (PLSE) to Release Earnings on Thursday

Pulse Biosciences (NASDAQ:PLSE) will likely be releasing its Q4 2025 results after the market closes on Thursday, February 19th. Analysts expect the company to announce earnings of ($0.32) per share and revenue of $0.2250 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 19, 2026 at 4:30 PM ET.

Pulse Biosciences Trading Up 5.6%

PLSE stock opened at $25.25 on Thursday. The firm has a 50-day moving average price of $14.97 and a 200-day moving average price of $15.66. Pulse Biosciences has a 12 month low of $12.56 and a 12 month high of $26.30. The stock has a market capitalization of $1.71 billion, a P/E ratio of -22.35 and a beta of 1.77.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Mizuho set a $30.00 target price on shares of Pulse Biosciences in a research report on Friday, February 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $26.00.

Insider Transactions at Pulse Biosciences

In other news, insider Kevin Patrick Danahy sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $21.45, for a total value of $429,000.00. Following the transaction, the insider owned 43,298 shares in the company, valued at approximately $928,742.10. The trade was a 31.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 74.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of PLSE. Portolan Capital Management LLC bought a new position in Pulse Biosciences in the third quarter worth approximately $1,809,000. Brooklyn Investment Group boosted its stake in shares of Pulse Biosciences by 5,313.1% in the 3rd quarter. Brooklyn Investment Group now owns 30,259 shares of the company’s stock worth $536,000 after buying an additional 29,700 shares during the last quarter. UBS Group AG grew its holdings in shares of Pulse Biosciences by 53.4% in the third quarter. UBS Group AG now owns 76,856 shares of the company’s stock valued at $1,360,000 after acquiring an additional 26,739 shares in the last quarter. Bank of America Corp DE increased its position in shares of Pulse Biosciences by 2.7% during the third quarter. Bank of America Corp DE now owns 804,960 shares of the company’s stock valued at $14,248,000 after acquiring an additional 21,424 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in Pulse Biosciences during the first quarter worth $323,000. Institutional investors and hedge funds own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.